If you are relatively lean and trying to shed the last few pounds of stubborn fat, the marginal benefit might be noticeable, though still unproven in rigorous clinical settings
Of greater concern are potential risks from combination use: Hypoglycaemia risk: Retatrutide enhances insulin secretion in a glucose-dependent manner, which carries a low intrinsic hypoglycaemia risk when used alone
It also increases the body's ability to use fat for energy while slowing down the process that converts excess calories into fat
Given the rise in autoimmunity, side effects of multiple medications affecting this pathway and crashing levels of soil cobalt due to glyphosate this why this pathway is wrecked in so many people and why injection are needed by so many and often at high frequency.
Use of MOUNJARO for this indication is supported by a 30-week, randomized, double-blind, placebo-controlled trial with a 22-week open label extension in 99 pediatric patients [see Clinical Studies (14.5)]
Some centres extend this to six months or beyond, but only where clinically indicated for example, in patients with ongoing reflux symptoms or confirmed gastro-oesophageal reflux disease (GORD)
